

# **Observed time to HIV treatment initiation in the era of** same-day initiation in Malawi, South Africa, and Zambia

<u>Amy Huber<sup>1</sup></u>, Kamban Hirasen<sup>1</sup>, Bevis Phiri<sup>2</sup>, Timothy Tcherini<sup>3</sup>, Andrews Gunda<sup>3</sup>,

Hilda Shakwelele<sup>2,</sup> Prudence Haimbe<sup>2</sup>, Bilaal Matola<sup>4</sup>, Lloyd Mulenga<sup>5</sup>, Sydney Rosen<sup>1,6</sup>

1. Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; 2. Clinton Health Access Initiative, Lusaka, Zambia. 4. Clinton Health Access Initiative, Lilongwe, Malawi; 4. Ministry of Health, Lilongwe, Malawi; 5. Ministry of Health, Lusaka, Zambia; 6. Department of Global Health, Boston University School of Public Health, MA, United States

#### BACKGROUND

Since 2017 global guidelines have recommended "same-day initiation" (SDI) of antiretroviral treatment (ART) for patients considered ready for treatment on the day of HIV diagnosis.

## In 2018-2019, uptake of same-day ART initiation was very high in Zambia (91%) and Malawi (87%) but more modest in South Africa (57%)

- In clinical trials of SDI, most improvement came from reducing loss to follow up between testing HIV positive and initiating ART.
- Some observational studies report that patients actually starting ART on the same day have higher loss to follow up during the first year after initiation, but these studies compare outcomes of SDI patients to outcomes among those who started later, ignoring patients who never started ART at all.
- Many countries in sub-Saharan Africa have incorporated a SDI option into national guidelines, but uptake of SDI is not well documented.
- Time intervals from HIV diagnosis or first HIV-related healthcare interaction to initiation of ART are not routinely reported.
- We estimated average time to ART initiation for all patients eligible for initiation at 12 public healthcare facilities in Malawi, 5 in South Africa, and 12 in Zambia.

#### **METHODS**

Sequentially enrolled patients who were eligible to start ART

#### **RESULTS**

- Enrolled 850 patients in Malawi, 535 in South Africa, and 1,990 in Zambia (Table 1).
- Proportions offered and accepting same-day ART initiation were (Table 2):
  - 87% Malawi
  - 57% South Africa
  - 91% Zambia
- In Malawi, most patients who did not receive SDI had also not initiated ART ≤6 months.
- In South Africa, an additional 13% of patients initiated  $\leq 1$  week, but 22% had no record of initiation  $\leq 6$  months. Among those who did initiate within 6 months in Zambia, nearly all started ≤1 week.
- There were no major differences by gender.

lable 1. C	haracteristics	s of study sit	es and no	pulation

Characteristic	Malawi	South Africa	Zambia	
Study sites (n)	12 in Blantyre, Chiradzulu,	5 in Ehlanzeni and	12 in Central and	
	and Lilongwe Districts	King Cetshwayo Districts	Lusaka Provinces	
Setting (% rural v urban)	58%	50%	33%	
Participants (n)	850	535	1990	
Participants % female	51%	58%	51%	
Participants age groups				
18-29	32%	33%	33%	
30-39	36%	41%	39%	
40-49	20%	18%	20%	
50+	10%	8%	8%	
Missing	2%	0%	0%	

between January 2018 and June 2019

- Reviewed their medical records from the point of HIV treatment eligibility (HIV diagnosis or first HIV-related interaction with the clinic) to the earlier of treatment initiation or 6 months.
- Estimated the proportion of patients initiating ART at their original healthcare facilities on the same day or within 7, 14, 30, or 180 days of baseline, stratified by country and gender.

### Table 2. Mean time to ART initiation after HIV diagnosis or first HIV-related clinic visit, in days

Time to ART initiation	Malawi (n=850)			South Africa (n=535)			Zambia (n=1,990)		
after HIV diagnosis or first	Total	Male	Female	Total	Male	Female	Total	Male	Female
HIV-related clinic visit	(n=850)	(n=412)	(n=438)	(n=535)	(n=233)	(n=302)	(n=1990)	(n=973)	(n=1017)
(n, %)									
0 days (same-day )	739 (86.9%)	363 (88.1%)	376 (85.8%)	304 (56.8%)	131 (56.2%)	173 (57.3%)	1,818 (91.4%)	886 (91.1%)	932 (91.6%)
7 days	14 (1.6%)	7 (1.7%)	7 (1.6%)	69 (12.9%)	33 (14.2%)	36 (11.9%)	96 (4.8%)	57 (5.9%)	39 (3.8%)
14 days	4 (0.5%)	2 (0.5%)	2 (0.5%)	12 (2.2%)	3 (1.3%)	9 (3.0%)	34 (1.7%)	12 (1.2%)	22 (2.2%)
30 days	5 (0.6%)	2 (0.5%)	3 (0.7%)	17 (3.2%)	11 (4.7%)	6 (2.0%)	14 (0.7%)	8 (0.8%)	6 (0.6%)

